B-cell

Overview

B cells are lymphocytes derived from hematopoietic stem cells in bone marrow that play central roles in adaptive immunity through both antibody production and antigen presentation. These cells are characterized by the expression of B cell receptors (BCRs) and major histocompatibility complex (MHC) class II molecules, enabling them to recognize antigens and present processed peptide fragments to T cells. During immune responses, B cells undergo clonal expansion and differentiation into plasma cells that synthesize antibodies, or into memory cells that provide long-lived protective immunity. Their developmental progression includes transition through germinal centers within lymphoid tissues, where B cells interact with follicular helper T cells and undergo somatic hypermutation and class switching to generate functionally diverse antibody isotypes.

Beyond antibody production, B cells function as professional antigen-presenting cells (APCs) that regulate immune responses through direct interactions with T cells via co-stimulatory molecules such as CD86 and ICOSL, and through modulation of inflammatory microenvironments in lymph nodes and tertiary lymphoid structures. Distinct B cell subsets—including classical and atypical B cells—exhibit specialized roles in tissue-resident immunity and systemic immune control, with genetic variants affecting B cell-specific gene expression contributing to susceptibility for autoimmune, infectious, and neurodegenerative diseases. The therapeutic targeting of B cells has proven effective in multiple disease contexts including autoimmune conditions and cancer, underscoring their importance as both central effectors of protective immunity and drivers of pathological inflammation when dysregulated.

Recent Publications Summary

Recent research has revealed B cells as central orchestrators of both humoral and cellular immune responses, with diverse roles spanning vaccine efficacy, autoimmune pathology, and tumor immunity. In vaccine development, epitope avidity—the combined binding strength imparted by multivalent presentation—shapes B cell immunodominance hierarchies and germinal center seeding 42585293Aug, while intranasal adenovirus vaccines elicit durable mucosal and systemic B cell responses including serum and saliva immunoglobulin A and broad neutralizing antibodies 42497177Jul. B cells function as antigen-presenting cells critical for CD4+ T cell priming in response to multivalent nanoparticle vaccines, with evidence that B cells alone can be sufficient to drive naive T cell responses in the absence of conventional dendritic cell antigen presentation 42085184May. Gene-edited B lymphocytes derived from hematopoietic stem and progenitor cells produce long-term, therapeutic levels of antibodies following antigen-driven clonal expansion and differentiation into plasma cells 41990179Apr, while memory B cells demonstrate progressively increasing variant-binding breadth and somatic hypermutation over time after vaccination 41928519Apr.

B cells play pathogenic roles in multiple autoimmune and inflammatory conditions through distinct mechanisms. A disease-causal genetic variant (rs57494551) regulates CXCR5 expression in B cells and correlates with disease activity in primary biliary cholangitis 42573624Aug, while orthodontic mechanical forces trigger expansion of CD69+ B cells that drive systemic pathology through immunoglobulin M production 42543382Aug. B cells regulate disease transfer in experimental autoimmune encephalomyelitis 42030372Apr. Therapeutic B cell-targeting approaches show promise in diverse contexts: a lymph node-targeted nano-prodrug inhibited antigen-presenting B cells and germinal center formation in a model of collagen-induced arthritis prevention 41687284Feb, while network meta-analysis identified B cell-targeting therapies among effective treatments for myasthenia gravis 42467874Jul.

B cells interact dynamically with other immune cells within specialized tissue microenvironments to shape adaptive immune responses and antitumor immunity. Within tertiary lymphoid structures following neoadjuvant therapy, B cells spatially associate with precursor exhausted T cells and promote their invigoration via ICOSL-ICOS and CD86-CD28 interactions 42339989Jun. B cell phenotypes and receptor genetic features contribute to antibody breadth, with atypical B cells and class-switched memory cells preferentially enriched for antigen binding against rapidly mutating viral variants 41928519Apr. Genetic studies implicate B cell-specific gene regulatory networks in Alzheimer's disease risk 42331779Jun, while defective B-cell reconstitution following hematopoietic stem cell transplantation correlates with acquired changes in the bone marrow microenvironment, particularly reduced production of supportive cytokines by stromal cells 41544216Jan.

What Changes, What Holds

1. B lymphocytes alone suffice to prime naive CD4+ T cell responses in vaccine contexts
NEW DIRECTION Sufficiency without dendritic cell participation 42085184May establishes B cells as autonomous antigen presenters rather than adjunctive to professional dendritic cells. Gene-edited B lymphocytes further demonstrate therapeutic potential 41990179Apr, producing sustained antibody levels through controlled antigen-driven differentiation—a platform previously absent from literature on engineered B cell therapeutics.

2. CXCR5 variants in B cells determine disease activity in primary biliary cholangitis
REINFORCES Expression of CXCR5, regulated by disease-causal rs57494551, correlates directly with disease activity 42573624Aug, exemplifying the baseline's principle that B cell-specific genetic variants contribute to autoimmune susceptibility. Concurrent findings on CD69+ B cell expansion and B cell-targeting efficacy 42467874Jul further confirm the established roles of B cells as central autoimmune drivers and valid therapeutic targets.

3. Bone marrow stromal cytokine support limits B cell recovery after hematopoietic stem cell transplantation
NEW DIRECTION Stromal cell-derived cytokines emerge as a microenvironmental rate-limiting factor in post-HSCT B cell reconstitution 41544216Jan, representing tissue-mediated control mechanisms absent from the baseline's emphasis on intrinsic B cell development. Spatial B cell-T cell interactions in tertiary lymphoid structures and B cell genetic networks in Alzheimer's disease, also noted within this paragraph, reinforce rather than revise existing understanding.

Overview update candidates: gene-edited B cells producing sustained therapeutic antibodies; stromal cell cytokines required for B cell reconstitution after hematopoietic stem cell transplantation.